Product Name: MK-3475

4 trials

Sponsors

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., (Merck), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Conditions

Gastric or Gastroesophageal Junction AdenocarcinomaLung cancer MedDRA version: 20.0 Level: LLT Classification code 10066490 Term: Progression of non-small cell lung cancer System Organ Class: 100000004864Non-Small Cell Lung Carcinoma

Phase 2

MK-3475 vs. Docetaxel in Second-Line Non-Small Cell Lung Cancer

Active, not recruitingEUCTR2012-004391-19-DK

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., (Merck)Lung cancer MedDRA version: 20.0 Level: LLT Classification code 10066490 Term: Progression of non-small cell lung cancer System Organ Class: 100000004864

Start: 2013-09-16Target: 920Updated: 2020-11-23

Phase 3

MK-3475 versus SOC in 1L Subjects with PD-L1 Strong Metastatic NSCLC

Active, not recruitingEUCTR2014-000323-25-IE

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.Non-Small Cell Lung Carcinoma

Start: 2014-08-05Target: 300Updated: 2021-07-05

OS Study of Pembrolizumab (MK-3475) vs. SOC in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic NSCLC (Keynote 042)

Active, not recruitingEUCTR2014-001473-14-SE

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.Non-Small Cell Lung Carcinoma

Start: 2014-10-14Target: 1250Updated: 2021-10-08

A Phase III Study of Pembrolizumab in Subjects with Gastric Cancer

Active, not recruitingEUCTR2014-005241-45-FI

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.Gastric or Gastroesophageal Junction Adenocarcinoma

Start: 2015-04-22Target: 720Updated: 2021-06-21